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Summary The aim of this investigation was to examine the possibility of analysing TP53 mutations in
archival paraffin-embedded material with the constant denaturant gel electrophoresis (CDGE) method. We
extracted DNA from 193 archival primary breast carcinoma samples, diagnosed in 1981-83; further analysis
was possible for 186 of these. TP53 mutations in exons 5-8 were detected with CDGE in 30 samples (16.1%)
and 17 of these mutations were confirmed by sequencing. Immunohistochemistry demonstrated TP53 nuclear
accumulation in 58 tumours (31%). A strong association between the presence of TP53 mutations and TP53
immunostaining was observed (P<0.001). Our mutation and immunohistochemistry results are in agreement
with other findings based on fresh tumour tissue. TP53 abnormalities were significantly related to high S-phase
fraction, low oestrogen receptor (ER) content and high tumour grade. Survival of patients with TP53
abnormalities, in the group as a whole, did not differ from patients with normal TP53. Our study did, however,
show that patients with abnormal TP53 had a significantly shorter post-recurrence survival (P=0.005) than
patients with normal TP53.
Keywords: paraffin-embedded archival tissue; breast cancer; TP53 mutation analysis; constant denaturant gel
electrophoresis; immunohistochemistry; prognosis
One of the most studied genes in cancer research is the TP53
tumour-suppressor gene. Since its discovery in 1979 (Lane et
al., 1979) it has been found to be the most commonly altered
gene in human tumours (Hollstein, 1991). The TP53 gene,
which is 20 kb long and consists of 11 exons and 10 introns,
is located on the short arm of chromosome 17. It encodes a
393 amino acid phosphoprotein (55 kDa), normally expressed
at a low level in cells.
Several studies indicate that the role of this protein is to
maintain the genomic integrity of the cell (Livingstone et al.,
1992; Yin et al., 1992; Eyfj6rd et al., 1995). How TP53
achieves this goal is still unclear but a picture is emerging. In
response to DNA damage, TP53 induces cell-cycle arrest
(Kastan et al., 1992) by downstream regulation of several
genes such as the p2] gene (El-Deiry et al., 1993, 1994),
which induces G1 cell-cycle arrest, and GADD45, which
suppresses cell growth, inhibits DNA replication and induces
DNA repair (Smith et al., 1994; Zhan et al., 1994). The G1
arrest provides time for DNA repair before the cell replicates
its DNA in the S-phase. Studies also indicate that TP53
might have a role in apoptosis (Lowe et al., 1993) and now
more recently in DNA repair (Wang et al., 1994, 1995). All
these findings emphasise the importance of TP53's role as the
guardian of the genome' (Lane, 1992).
As reviewed by Greenblatt et al. (1994), inactivation of the
TP53 protein (e.g. by mutations or interaction with cellular
or viral proteins) has been implicated in the development of
many types of human cancers and it may be a critical step in
the formation of cancer because it affects the response of the
cell to DNA damage.
Alterations of TP53 are common in breast cancer,
although the reported mutation frequency does vary.
Immunohistochemical studies (IHCs), based on detecting
abnormal accumulation of TP53 protein, report that 16-
58% of breast tumours show immunostaining indicating
mutation (Lipponen et al., 1993; Cunningham et al., 1994;
MacGrogan et al., 1995) whereas DNA-based methods find
TP53 mutations in 14-40% of the tumours analysed (Elledge
et al., 1993; Saitoh et al., 1994; Bergh et al., 1995). Several
studies show that TP53 abnormalities (TP53 overexpression
and/or TP53 mutations) are an indicator of increased
malignant potential and worse prognosis in breast cancer
patients (Andersen et al., 1993; Barnes et al., 1993; Bergh et
al., 1995; Borg et al., 1995; MacGrogan et al., 1995;
Thorlacius et al., 1995).
The polymerase chain reaction (PCR) technology provides
the tools to use archival clinical material in molecular studies.
Here we examine the possibility of analysing TP53 mutations
with the PCR-based constant denaturant gel electrophoresis
(CDGE) method on archival breast carcinoma samples. We
analysed TP53 mutations and abnormal protein expression in
186 archival breast carcinomas, diagnosed during 1981-83.
The results were compared with data from fresh tumour
tissue and the association between TP53 abnormalities and
various prognostic factors and survival is examined.
Materials and methods
Tissue samples
Samples from 193 primary breast carcinomas, diagnosed
during 1981-83, were obtained from the archives of the
Department of Pathology, University Hospital of Iceland.
The samples are derived from 70% ofprimary invasive breast
cancer tumours diagnosed in Iceland during the study period.
The tissue samples had been routinely formalin fixed in 10%
formalin, paraffin embedded and then stored at room
temperature. The patients median age at diagnosis was 62
years (range 31-91 years) and the median follow-up time was
10 years. Clinicopathological information for patients,
presented in Table I, was obtained from the Departments
of Oncology and Pathology of the University Hospital, and
the Icelandic Cancer Registry. While assessing the TP53
changes and other variables that were potentially related to
survival, the investigators were blinded with respect to patient
identity.
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DNA preparation
DNA was extracted from tumour tissues embedded in
paraffin blocks as previously described (Wright et al., 1990).
Briefly, dry sections, 10 ,um thick were sliced from each
paraffin-tissue block and placed in sterile 1.5 ml Eppendorf
tubes. To avoid cross-contamination of samples the
microtome blade was carefully cleaned with xylene between
each block. The paraffin was removed with two extractions of
octane followed by two 100% ethanol washes. The tissue was
pelleted after each extraction/wash by 5 min centrifugation in
a microfuge at full speed. The paraffin-free samples were then
incubated for 24 h at 371C in digestion buffer (50 mM Tris-
pH 8.5, 1 mM EDTA, 0.5% Tween 20 and 200 mg ml-1 of
Proteinase K). Protease inactivation was performed by
10 min incubation at 95°C. The samples were stored at
-20°C in small aliquots.
DNA analyses
The tumour samples were screened for mutations in the
evolutionary conserved regions of the TP53 gene, exons 5-8,
with the CDGE method. The PCR and CDGE electrophor-
esis conditions were as previously described (B0rresen et al.,
1991; Smith-Sorensen et al., 1993). The thermocycling
parameters were modified for the archival DNA by
lengthening the time at each temperature and increasing the
number of cycles. To avoid non-specific priming and improve
amplification the 'hot start' method was used for all samples
(Chou et al., 1992). Amplification was achieved by 35 cycles
of denaturing for 75 s at 94°C, annealing for 90 s at 55°C,
extension for 90 s at 72°C. After PCR amplification,
heteroduplex formation was ensured by denaturing the
PCR products for 3 min at 94°C and then keeping them at
65°C for 60 min.
To confirm abnormalities detected with the CDGE
method the samples were reamplified and submitted to
DGGE electrophoresis (perpendicular denaturant gradient
gel electrophoresis). Samples that showed aberrantly migrat-
ing bands with both methods were considered to be mutants.
PCR fragments with mobility shifts in exon 6 were digested
with the restriction enzyme TaqI to detect the presence of the
neutral A>G polymorphism in codon 213. Mutations were
further confirmed by direct sequencing as described pre-
viously (B0rresen et al., 1991).
Table I Clinical parameters for 186 primary tumours
No. of tumours (%)
Tumour type (n= 186)
Infiltrating ductal
Lobular
Other
Tumour size (n = 181)
<20 mm
>20 mm
Lymph-node status (n 152)
Negative
Positive
Oestrogen receptor (n- 111)
<10 fmolmg-' protein
> 10 fmolmg-' protein
Progesterone receptor (n = 101)
<25 fmol mg-1 protein
>25 fmolmg-, protein
Malignancy grade (n= 145)
I
III
165 (89)
5 (3)
16 (8)
75 (41)
106 (59)
79 (52)
73 (48)
39 (35)
72 (65)
51 (50)
50 (50)
39 (27)
58 (40)
48 (33)
Immunohistochemistry
Immunostaining was performed on tissue sections cut
adjacent to the sections used for DNA extraction. Sections
4,um thick were mounted on slides, dewaxed in xylol and
rehydrated in graded ethanol solutions. Tissue sections were
then incubated in citrate buffer (pH 6.0) for 2 x 5 min in a
850 W microwave oven at full power. The sections were
stained with the monoclonal mouse anti-human p53 anti-
body, DO-7 (Novocastra). DO-7 recognises a denaturation-
resistant epitope located between amino acids 35 and 45, and
reacts with both wild-type and mutant p53 protein. The
antibody was used at a dilution of 1: 50 and incubated for
90 min at room temperature. The slides were then washed
and staining detected with the LSAB (Dako) reagent
according to the manufacturer's protocol. The slides were
independently scored by two investigators and discrepancies
were resolved by subsequent consultation.
Hormone receptors
Oestrogen receptor (ER) content was determined with
isoelectric focusing, and progesterone receptor (PgR) content
with the multiple point dextran-coated charcoal method and
Scatchard analysis. The prognostic cut-off value adopted for
ER-positive tumours was 10 fmol mg-' protein and
25 fmol mg-' protein for PgR-positive tumours.
DNA ploidy and S-phase
The DNA content in individual cell nuclei was analysed in a
FACScan flow cytometer after staining with propidium
iodide. The percentage of cell nuclei corresponding to the
S-phase fraction was calculated with a three-phase plani-
metric method sum of Broad-end Rectangles (SOBR). The
median S-phase value was used as a prognostic cut-off value
(<7% vs >7%).
Malignancy grade
A modified version of the Bloom and Richardson grading
system was used, which gives equal importance to three
tumour features, i.e. tubule formation, nuclear pleomorphism
and mitotic count, giving three prognostic categories, low risk
(I), intermediate risk (II) and high risk (III).
Statistical analysis
For univariate comparisons between the two TP53 categories,
in relation to continuous and categorical prognostic
variables, The Mann-Whitney U-test and the chi-square
test were applied respectively. Differences between Kaplan-
Meier survival curves were assessed with the log-rank test,
whereas Cox's (1972) proportional hazards model was used in
the multivariate analysis. The following parameters were
included, lymph-node status, tumour size, S-phase fraction,
TP53 mutations, TP53 expression and age at diagnosis. Three
different end points were applied for the survival analysis;
locoregional or distant recurrence (disease-free survival),
death from breast cancer (breast cancer corrected survival)
and death from any cause (overall survival). Only the last end
point was applied for the post-recurrence survival, which was
calculated from the date of manifest first distant recurrence.
Results
TP53 mutation analyses
The PCR-CDGE analysis was successful for 186 of the
samples. Seven samples were excluded from the study owing
to poor DNA quality. Thirty-one TP53 mutations were
found in 30 samples (16.1%) (Table II). Twelve mutations
were detected in exon 5 (39%), three in exon 6 (10%), nine in
exon 7 (29%) and seven in exon 8 (22%). Figure la and billustrates two examples of TP53 gene mutations detected by
CDGE and DGGE.
Seventeen mutations were confirmed by sequencing
(Figure lc), 15 point mutations (12 missense, two sense and
one nonsense), one deletion and one insertion (Table II). One
tumour (no. 52, Table II) had two independent mutations in
exon 5. Ten point mutations were identified as G:C>A:T
transitions (67%), two A:T>G:C transitions (13%), one
(7%) G:C>C:G transversion and two (13%) A:T>T:A
transversions. In seven samples the sequencing reaction was
successful but no mutation could be detected. Nuclear
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accumulation of TP53 protein was detected in five of those
samples. No sequencing reaction could be performed in seven
other samples owing to unsuccessful PCR amplification. Four
of these samples had nuclear TP53 protein accumulation.
TP53 immunohistochemistry analysis
Positive TP53 nuclear immunostaining was found in 58
tumours (31%). Of these 26 (45%) were graded as weak (+),
13 (22%) as moderate (+ +) and 19 (33%) as strong
(+ + +). Cells were scored positive (Figure 2) if immuno-
Table II TP53 mutations and nuclear TP53 protein accumulation
Tumour Tumour Functional Amino acid Immuno-
no. cells (%) Exon CDGE Codon domain Mutation substitution staining
43 60 5 Pos NI Pos+ + +
163 80 5 Pos 138 S2 GCC>GCT Ala>Ala Pos+ + +
129 75 5 Pos 163 L2 TAC>TGC Tyr>Cys Pos+ +
8 85 5 Pos 173 L2 GTG>ATG Val>Met Pos+ + +
50 75 5 Pos 175 L2 CGC>CAC Arg>His Pos+ + +
52 80 5 Pos 175 L2 CGC>CGT Arg>Arg Pos+ + +
52 80 5 Pos 176 L2 TGC>AGC Cys>Ser Pos+ + +
47 50 5 Pos 179 L2 CAT>CGT His>Arg Pos+ + +
59 80 5 Pos 179 L2 CAT>CTT His>Leu Pos+
180 70 5 Pos 181 L2 CGC>TGC Arg>Cys Neg
48 75 5 Pos NI L2 Pos+ + +
139 80 5 Pos 168-170 L2 frameshift 7bp deletion Neg
3 25 6 Pos ND Pos+ +
40 95 6 Pos NI - Neg
5 80 6 Pos 213 S6 CGA>TGA Arg>Stop Neg
19 80 7 Pos ND L3 - - Pos+
24 95 7 Pos ND L3 - - Pos+
42 50 7 Pos ND L3 - - Pos+ + +
44 50 7 Pos ND L3 - - Neg
7 50 7 Pos ND L3 - - Pos +
125 35 7 Pos NI L3 - - Pos+ +
26 35 7 Pos 245 L3 GGC>AGC Gly>Ser Pos+ +
136 30 7 Pos 245 L3 GGC>AGC Gly>Ser Pos+ +
150 80 7 Pos 245 L3 GGC>GCC Gly>Ala Pos+ +
87 100 8 Pos NI - - - Pos+ + +
20 40 8 Pos ND - - - Neg
37 100 8 Pos NI - - - Neg
100 95 8 Pos NI - - - Pos+ + +
110 65 8 Pos 273 S1O CGT>TGT Arg>Cys Pos+ + +
18 40 8 Pos from 273 SlO frameshift insertion Neg
64 80 8 Pos 278 H2 CCT>TCT Pro>Ser Pos+ + +
ND, not determined owing to unsuccessful PCR amplification; NI, mutation not identified by sequencing; Pos
weak staining; Pos + +, moderate staining; Pos + + +, strong staining.
a
2 3 4
b
heterodunlexes wt mutant
c
G A T C
.. .. ....
.. ...
Figure 1 Mutation analysis of the TP53 gene. (a) Constant denaturant gel electrophoresis (CDGE) of exon 6 PCR fragment. No
mutation was found in samples in lanes 1 and 2, lane 3 is a known codon 194 mutant (TTC>TTT) and lane 4 is tumour no.40. The
12.5% polyacrylamide gel contains 46% denaturant and was run for 2h at 560C at 80V constant. (b) Perpendicular denaturing
gradient gel electrophoresis (DGGE) of exon 5 (hsp A) fragment of tumour no.43. The fragment was analysed on a 12.5%
polyacrylamide gel with a 20-70% gradient of denaturant. (c) Sequencing analysis of PCR fragment exon 8 of tumour no. 64. A
substitution CCT>TCT is seen in codon 278.
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staining was found in the nucleus (scoring according to
Fisher et al., 1994). The concordance between TP53
mutations and TP53 protein accumulation was highly
significant (P<0.001). Nuclear TP53 protein accumulation
was detected in 22 of 30 mutated (according to CDGE
analysis) samples (82% showing strong or moderate staining)
and 36 of 156 samples with no detected mutation (38% with
strong or moderate staining). Of the 13 tumours detected
with missense mutations, 11 showed positive immunostaining
whereas the two tumours with frameshift mutations and the
tumour with nonsense mutation showed no staining (Table
II).
TP53 relationship to clinical and histopathological parameters
The relationship between TP53 abnormalities and age at
diagnosis, tumour size, lymph-node involvement, ER/PgR
content, S-phase fraction and malignancy grade is shown in
Table III. TP53 abnormalities were significantly related to
high S-phase fraction, low ER content and high tumour
grade. TP53 abnormalities were more common in tumours
with low PgR content but this association was not significant.
No obvious relationship was found with age, tumour size and
lymph-node involvement.
TP53 and survival analyses
In the whole study group, TP53 mutations (Figure 3a and b)
and TP53 expression did not have a significant effect on
prognosis, in overall (OS), breast cancer corrected (BCCS)
and disease-free survival (DFS). In a multivariate analysis
only lymph node status and S-phase fraction retained
significant prognostic effects. There was, however a
significant effect on survival in a certain subgroup of
patients. Thus, TP53 mutations had a significant prognastic
value for patients that were treated for recurrent disease
(P=0.005), Figure 4.
Discussion
To the best of our knowledge the present study is the first to
use CDGE TP53-mutation analysis on archival breast cancer
tissue. We present here results from mutation screening of
nearly 200 archival samples. Most previously published
studies on mutation analysis of archival material have been
based on much smaller sample size, or only a selected subset
ofpatients (McManus et al., 1994; Niwa et al., 1994; Wang et
al., 1995).
DNA analysis of archival material can, owing to DNA
degradation, be more time-consuming and result in less clear
and readable data than achieved when using fresh material.
Our results show that the majority of the samples were
suitable for amplifications for the CDGE analysis (product
size 130-190 bp). However, amplification of larger PCR
products (>300 bp) for the direct sequencing was less
successful, probably owing to DNA degradation in the
archival tissue.
Figure 2 TP53 immunostaining of tumour no.87 with DO-7
antibody. Original magnification x 500. Nuclear immunostaining
detected in a high proportion of tumour cells.
Table III TP53 abnormalities in relation to clinical-histopathological parameters
TP53
mutation and
TP53 protein protein
TP53 mutation accumulation accumulation
Characteristics (oo) P-value (M0) P-value (%) P-value n
All patients 30 (16) 58 (31) 66 (35) 186
Age (years) 0.69 0.21 0.43
<50 7 (15) 14 (30) 17 (37) 46
>50 23 (16) 37 (26) 45 (32) 140
Tumour size 090509 uo
20mm 8 (11) 24 (32) 26 (35) 75
>20mm 22 (21) 30 (28) 36 (34) 106
Lymph-node
involvement 0.81 0.42 0.58
Node neg 14 (18) 26 (33) 29 (37) 79
Node pos 12 (16) 20 (27) 24 (33) 73
ER content 0.16 0.13 0.03
<lOfmolmg-1 10 (26) 17 (44) 20 (51) 39
>10fmolmg-1 7 (10) 17 (24) 18 (25) 72
PgR content 0.15 0.39 0.19
<25fmolmg-' 10 (20) 19 (37) 21 (41) 51
25fmolmg-l 6 (12) 12 (24) 13 (26) 50
S-phase 0.003 0.04 0.003
<7% 6 (7) 21 (25) 22 (27) 83 >7o% 20 (22) 32 (35) 38 (41) 92
Malignancy grade 0.009 0.004 0.0001
I 1 (3) 3 (8) 4 (10) 39
II 9 (16) 19 (33) 20 (35) 58
III 14 (29) 21 (44) 27 (56) 48Our results show clearly the high sensitivity of the CDGE
mutation analysis as we were able to identify mutations in
sections, without microdissection, with as little as 25-35% of
tumour (e.g. samples no. 3, 26, 136 and 125, Table I). The
sequence analysis on the other hand had a lower sensitivity in
a
Time (months)
126
26
142
26
94
17
No. of patients at risk
60
Time (months)
85
16
No. of patients at risk
Figure 3 Overall survival (a) and disease-free survival (b) in
relation to TP53 mutations. The number of patients at risk at
time zero, 60 and 120 months is shown for each category. ( ),
TP53 wt; (- - -), TP53 mut.
54
10
P= 0.005
40
Time (months)
11
0
No. of patients at risk
80
2
0
Figure 4 Post-recurrence survival in relation to TP53 mutations.
The number of patients at risk at time zero, 40 and 80 months is
shown for each category (see category definition in Figure 3).
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detecting mutations in the archival material. In four of the
seven samples, where sequencing was unsuccessful, the
mutation identification in CDGE and DGGE was based on
the presence of heteroduplexes due to a very faint mutant
band (Figures la and b).
The frequency of mutations in our TP53 analysis of the
archival material is in concordance with previous findings.
The observed TP53 mutation frequency, 16.1%, is similar to
the frequency of 17.8% found in our previous study on fresh
tumour tissue (Thorlacius et al., 1995), slightly lower than the
overall calculated frequency, 20% (B0rresen et al., 1995) but
within the range of other reported frequencies, 14-40%
(Elledge et al., 1993; Saitoh et al., 1994). The mutation
distribution (according to CDGE analysis) and the type of
mutations (according to the DNA sequencing) identified is
very similar to other studies (Greenblatt et al., 1994; B0rresen
et al., 1995; Thorlacius et al., 1995). The majority of
mutations found are transitions (G:C>A:T). Transversion
frequency is slightly lower in our data as no G:C>T: A and
A:T>C: G transversions were identified.
Immunohistochemistry demonstrated TP53 nuclear accu-
mulation in 31% of the primary breast tumours. These
results are also in agreement with our previous findings
(33.7%, Thorlacius et al., 1995) using the CM-1 and DO-1
antibodies. A recent study using the DO-7 antibody
(MacGrogan et al., 1995) reports a similar proportion of
samples with nuclear staining (32%). Tissue sections used in
the mutation and immunohistochemistry analysis were taken
in succession from the same paraffin blocks, thus an identical
tumour cell population was used in these two studies. We
found a highly significant association between the presence of
TP53 mutations (CDGE analysis) and TP53 protein
accumulation, suggesting that TP53 immunostaining is
mainly due to TP53 mutations. No mutations were,
however, detected in 36 positively stained samples. Staining
in these cases may have been caused by mutations outside the
regions that were screened or by a different mechanism that
prolongs the half-life of the TP53 protein, such as mutations
in other genes involved in the TP53 pathway (Momand et al.,
1992). No TP53 immunostaining was detected in eight TP53
mutated tumours. The possibility that not all mutations result
in an increased half-life of the protein might explain why
some missense mutations do not show positive immunostain-
ing (such as sample no. 180). Samples with nonsense (no. 5)
or frameshift mutations (nos. 18 and 139) showed no
staining, as would be expected.
As reviewed by Greenblatt et al. (1994), TP53 abnormal-
ities are believed to be an early event in breast cancer tumour
progression. In this study we found no differences in lymph-
node involvement between patients with and without TP53
abnormalities. As metastatic lymph-node involvement is
believed to be a time-dependent factor reflecting the
chronological age of the breast tumour (Barr et al., 1992)
our observation may be interpreted as support for the above-
mentioned conclusion of Greenblatt et al.
In the present investigation tumours with TP53 abnorm-
alities tend to have aggressive biological behaviour reflected
by less tumour differentiation and higher proliferation rate. It
was therefore unexpected that, in the group as a whole,
patients with tumour TP53 abnormalities had similar survival
to patients with normal TP53 in their tumours. This finding
differs from our previous results (Thorlacius et al., 1995) and
results of many other investigations (Andersen et al., 1993;
Barnes et al., 1993; Bergh et al., 1995; Borg et al., 1995
MacGrogan et al., 1995). Our previous study of Icelandic
breast cancer patients diagnosed during 1987-90 showed
that women with TP53 mutations and TP53 nuclear staining
in their tumours had an elevated risk of dying from breast
cancer within 5 years (TP53 mut. RR=3.4, P=0.01, TP53
express. RR=3.2, P=0.01). We have no simple explanation
for the different prognostic relevance of TP53 abnormalities
in breast cancer patients diagnosed during 1981-83
compared with 1987-90. Our study did, however, show
that patients with TP53 abnormalities had a significantly
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shorter post-recurrence survival than patients with normal
TP53 status. This seems to indicate that tumours with
abnormal TP53 are more resistant to therapy than tumours
with normal TP53. It is known that cancer chemotherapeutic
drugs and radiation induce apoptosis (Kerr et al., 1994).
Studies on transformed cells, show that the TP53 gene is an
important component of the apoptotic pathway (Clarke et
al., 1993; Lowe et al., 1993). In vivo experiments in mice show
that tumour response to gamma irradiation and to the
chemotherapeutic drug doxorubicin is under the influence of
the TP53 status (Lowe et al., 1994). These results show that
defects in apoptosis caused by TP53 inactivation can produce
treatment-resistant tumours. A recent study (Bergh et al.,
1995) shows that adjuvant therapy, especially with tamoxifen,
along with radiotherapy seems to be of less value for breast
cancer patients with TP53 mutations and node-positive
tumours than patients without mutations.
In conclusion our data show that it is possible to use
archival material for TP53 mutation analysis and that results
are comparable with those obtained from fresh tumour tissue.
There was a slight trend towards poorer prognosis in overall
and breast cancer corrected survival for patients with TP53
abnormalities. A significant effect, however, was seen in post-
recurrence survival, suggesting that poor response to therapy
may be related to altered TP53 function.
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